Original ResearchInactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma
Graphical abstract
Keywords
Abbreviations used in this paper
Cited by (0)
CRediT Authorship Contributions Tomomi Hashiba (Investigation: Equal; Methodology: Equal; Writing – original draft: Supporting); Taro Yamashita (Conceptualization: Lead; Formal analysis: Equal; Funding acquisition: Lead; Investigation: Equal; Methodology: Equal; Project administration: Lead; Writing – original draft: Lead; Writing – review & editing: Lead); Hikari Okada (Data curation: Lead; Formal analysis: Lead; Investigation: Lead; Methodology: Lead; Writing – review & editing: Supporting); Kouki Nio (Investigation: Supporting; Methodology: Supporting; Resources: Supporting; Writing – review & editing: Supporting); Takehiro Hayashi (Resources: Supporting; Writing – review & editing: Supporting); Yoshiro Asahina (Resources: Supporting; Writing – review & editing: Supporting); Tomoyuki Hayashi (Resources: Supporting; Writing – review & editing: Supporting); Takeshi Terashima (Resources: Supporting; Writing – review & editing: Supporting); Noriho Iida (Resources: Supporting; Writing – review & editing: Supporting); Hajime Takatori (Resources: Supporting; Writing – review & editing: Supporting); Tetsuro Shimakami (Resources: Supporting; Writing – review & editing: Supporting); Kazunori Kawaguchi (Resources: Supporting; Writing – review & editing: Supporting); Kuniaki Arai (Resources: Supporting; Writing – review & editing: Supporting); Yoshio Sakai (Resources: Supporting; Writing – review & editing: Supporting); Tatsuya Yamashita (Resources: Supporting; Writing – review & editing: Supporting); Eishiro Mizukoshi (Resources: Supporting; Writing – review & editing: Supporting); Hiroyuki Takamura (Resources: Supporting; Writing – review & editing: Supporting); Tetsuo Ohta (Resources: Supporting; Writing – review & editing: Supporting); Masao Honda (Data curation: Equal; Resources: Supporting; Visualization: Supporting; Writing – review & editing: Supporting); Shuichi Kaneko (Supervision: Lead; Writing – review & editing: Supporting).
Conflicts of interest This author discloses the following: Shuichi Kaneko received a research grant from Bayer, the manufacturer of sorafenib and regorafenib. The remaining authors disclosed no conflicts.
Funding This study was supported by grants from the Joint Research in East Asia (16934588), the Japanese Ministry of Education, Culture, Sports, Science and Technology (18H02792, 18K19538, and 16671907), Practical Research for Innovative Cancer Control (18970618), Program for Basic and Clinical Research on Hepatitis of Japan Agency for Medical Research and Development (17929612), the CHOZEN project, and a research grant from Bayer.
- §
Authors share co-senior authorship.